#Denmark #Copenhagen #Parkinson's #Lundbeck #Lu AF28996

Lundbeck's Advancements in Parkinson's Research

Lundbeck, a leading biopharmaceutical company, has made significant strides in Parkinson's research, particularly with its investigational compound Lu AF28996 intended for those suffering from advanced stages of the disease. During the upcoming AD/PD™ 2026 conference in Copenhagen, Denmark, Lundbeck will present key findings from a Phase 1b proof-of-mechanism trial that demonstrate the compound's safety and early efficacy indicators.

Understanding Lu AF28996

Lu AF28996 is designed to engage the dopamine D1 and D2 receptors, which play a critical role in managing motor functions. This innovative treatment aims to alleviate symptoms characterized by drastic motor fluctuations—an issue frequently faced by patients even when adhering to current treatments.

The results from the Phase 1b trial reveal that the compound is generally well tolerated among participants, offering encouraging initial pharmacokinetic data that suggests it could effectively address motor-related challenges caused by Parkinson's disease. As Johan Luthman, EVP and Head of Research & Development, noted, these findings serve as pivotal evidence for the potential impact of Lu AF28996 and reinforce Lundbeck's commitment to advancing therapies aimed at severe neurological disorders.

Importance of This Research

The reality for those with advanced Parkinson's often includes troubling periods of reduced mobility, referred to as